The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
BTOG 2026 | Understanding staging challenges in pericystic lung cancer lesions
Matthew Evison, MD, MRCP, Manchester University Hospital NHS Foundation Trust, Manchester, UK, discusses the challenges of understanding and managing pericystic lesions in lung cancer, which account for 1% to 4% of lung cancers. Further research is needed to develop a framework for staging these lesions, and while solid nodules and sub-solid nodules have established frameworks for staging, pericystic lesions lack a clear framework, leading to potential under or over staging and treatment. This interview took place at the 2026 British Thoracic Oncology Group (BTOG) congress in Edinburgh, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Yeah, so this is a very well-recognized entity of lung cancer. It probably makes up between 1% to 4% of lung cancers. So very well-recognized, but really quite poorly understood and described within the published literature. So it’s been really important at this meeting that BTOG starts to shine a light on these lesions. And we probably have more questions than we do answers right now...
Yeah, so this is a very well-recognized entity of lung cancer. It probably makes up between 1% to 4% of lung cancers. So very well-recognized, but really quite poorly understood and described within the published literature. So it’s been really important at this meeting that BTOG starts to shine a light on these lesions. And we probably have more questions than we do answers right now. But the more we start to talk about it, the more we understand it, the more we research it, we’ll know what to do with these lesions. So we know what to do with solid nodules. And actually a solid nodule is dead easy to measure. And so it’s easy for us to stage. We also have a really good framework for sub-solid nodules, for ground glass nodules. We know exactly where to put them on a spectrum of staging. But we don’t have one for pericystic lesions. And it feels like we probably use some of those other frameworks to try and stage these lesions we don’t know if that’s the right thing to do and we don’t know if we are under staging things which means we could risk delaying treatment or if we could be over staging or over treating so it’s such an important area that we start to focus on
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
